SARS-CoV-2 mRNA vaccine BNT162b2 triggers a consistent cross-variant humoral and cellular response

References

• Dan JM, Mateus J, Kato Y, et al. Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. Science. 2021;371:6529. DOI:https://doi.org/10.1126/science.abf4063.
   Web of Science ®Google Scholar
• Widge AT, Rouphael NG, Jackson LA, et al. Durability of responses after SARS-CoV-2 mRNA-1273 vaccination. N Engl J Med. 2021;384:80–82. DOI:https://doi.org/10.1056/NEJMc2032195.
   PubMed Web of Science ®Google Scholar
• CDC. Coronavirus Disease. (COVID-19). Centers for Disease Control and Prevention 2020. https://www.cdc.gov/coronavirus/2019-ncov/variants/variant-info.html (accessed June 29, 2021). 2019.
   Google Scholar
• Chen RE, Zhang X, Case JB, et al. Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies. Nat Med. 2021;27(4):717–726. DOI:https://doi.org/10.1038/s41591-021-01294-w.
   PubMed Web of Science ®Google Scholar
• Collier DA, Marco AD, Ferreira IATM, et al. SARS-CoV-2 B.1.1.7 sensitivity to mRNA vaccine-elicited, convalescent and monoclonal antibodies. MedRxiv 2021. 2021;01(19):21249840. DOI:https://doi.org/10.1101/2021.01.19.21249840.
   Google Scholar
• Edara VV, Hudson WH, Xie X, et al. Neutralizing antibodies against SARS-CoV-2 variants after infection and vaccination. JAMA. 2021;325:1896. DOI:https://doi.org/10.1001/jama.2021.4388.
   PubMed Web of Science ®Google Scholar
• Jangra S, Ye C, Rathnasinghe R, et al. SARS-CoV-2 spike E484K mutation reduces antibody neutralisation. The Lancet Microbe. 2021;2; e283–e284. DOI:https://doi.org/10.1016/S2666-5247(21)00068-9.
   PubMedGoogle Scholar
• Liu Y, Liu J, Xia H, et al. Neutralizing activity of BNT162b2-elicited serum. N Engl J Med. 2021;384:1466–1468. DOI:https://doi.org/10.1056/NEJMc2102017.
   PubMed Web of Science ®Google Scholar
• Rees-Spear C, Muir L, Griffith SA, et al. The effect of spike mutations on SARS-CoV-2 neutralization. Cell Rep. 2021;34:108890. DOI:https://doi.org/10.1016/j.celrep.2021.108890.
   PubMed Web of Science ®Google Scholar
• Wang P, Nair MS, Liu L, et al. Antibody Resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. Immunology. 2021. DOI:https://doi.org/10.1101/2021.01.25.428137.
   Google Scholar
• Weisblum Y, Schmidt F, Zhang F, et al. Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants. ELife. 2020;9:e61312. DOI:https://doi.org/10.7554/eLife.61312.
   PubMed Web of Science ®Google Scholar
•  Xie X, Liu Y, Liu J, et al. Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited sera. Nat Med. 2021;27(4):620–621. DOI:https://doi.org/10.1038/s41591-021-01270-4.
   PubMed Web of Science ®Google Scholar
• Zani A, Caccuri F, Messali S, et al. Serosurvey in BNT162b2 vaccine-elicited neutralizing antibodies against authentic B.1, B.1.1.7, B.1.351, B.1.525 and P.1 SARS-CoV-2 variants. Emerg Microbes Infect. 2021;10:1–6. DOI:https://doi.org/10.1080/22221751.2021.1940305.
   Web of Science ®Google Scholar
• Tan CW, Chia WN, Qin X, et al. A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2–spike protein–protein interaction. Nat Biotechnol. 2020;38:1073–1078. DOI:https://doi.org/10.1038/s41587-020-0631-z.
   PubMed Web of Science ®Google Scholar
• Lau EHY, Tsang OTY, Hui DSC, et al. Neutralizing antibody titres in SARS-CoV-2 infections. Nat Commun. 2021;12:63. DOI:https://doi.org/10.1038/s41467-020-20247-4.
   PubMed Web of Science ®Google Scholar
• Kohmer N, Westhaus S, Rühl C, et al. Brief clinical evaluation of six high-throughput SARS-CoV-2 IgG antibody assays. J Clin Virol. 2020;129:104480. DOI:https://doi.org/10.1016/j.jcv.2020.104480.
   PubMed Web of Science ®Google Scholar
• Krammer F, Srivastava K, Alshammary H, et al. Antibody responses in seropositive persons after a Single dose of SARS-CoV-2 mRNA vaccine. N Engl J Med. 2021;384:1372–1374. DOI: https://doi.org/10.1056/NEJMc2101667.
   PubMed Web of Science ®Google Scholar
• Wei J, Stoesser N, Matthews PC, et al. Antibody responses to SARS-CoV-2 vaccines in 45,965 adults from the general population of the United Kingdom. Nat Microbiol. 2021;6:1–10. DOI: https://doi.org/10.1038/s41564-021-00947-3.
   Web of Science ®Google Scholar
• Muecksch F, Weisblum Y, Barnes CO, et al. Affinity maturation of SARS-CoV-2 neutralizing antibodies confers potency, breadth, and resilience to viral escape mutations. Immunity. 2021;54:1853–1868.e7. DOI:https://doi.org/10.1016/j.immuni.2021.07.008.
   PubMed Web of Science ®Google Scholar
• Cassaniti I, Percivalle E, Bergami F, et al. SARS-CoV-2 specific T-cell immunity in COVID-19 convalescent patients and unexposed controls measured by ex vivo ELISpot assay. Clin Microbiol Infect. 2021;27:1029–1034. DOI:https://doi.org/10.1016/j.cmi.2021.03.010.
   PubMed Web of Science ®Google Scholar
• Cremoni M, Ruetsch C, Zorzi K, et al. Humoral and cellular response of frontline health care workers infected by SARS-CoV-2 in nice, France: a prospective single-Center cohort study. Front Med. 2021;7. DOI:https://doi.org/10.3389/fmed.2020.608804.
   Google Scholar
• Gallagher KME, Leick MB, Larson RC, et al. SARS -CoV-2 T-cell immunity to variants of concern following vaccination. BioRxiv 2021. 2021;05(03):442455. DOI:https://doi.org/10.1101/2021.05.03.442455.
   Google Scholar
• Lilleri D, Cassaniti I, Bergami F, et al. SARS-CoV-2 mRNA vaccine BNT162b2 elicited a robust humoral and cellular response against SARS-CoV-2 variants. 2021. DOI:https://doi.org/10.21203/rs.3.rs-396284/v1.
   Google Scholar
• Bajaj V, Gadi N, Spihlman AP, et al. Aging, immunity, and COVID-19: how age influences the host immune response to coronavirus infections? Front Physiol. 2021;11. DOI:https://doi.org/10.3389/fphys.2020.571416.
   Google Scholar
• McCallum M, De Marco A, Lempp FA, et al. N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2. Cell. 2021;184:2332–2347.e16. DOI:https://doi.org/10.1016/j.cell.2021.03.028.
   PubMed Web of Science ®Google Scholar
• Wang R, Zhang Q, Ge J, et al. Analysis of SARS-CoV-2 variant mutations reveals neutralization escape mechanisms and the ability to use ACE2 receptors from additional species. Immunity. 2021;S1074-7613(21):00247–8. DOI:https://doi.org/10.1016/j.immuni.2021.06.003.
   Google Scholar
• Wang Z, Schmidt F, Weisblum Y, et al. mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants. Nature. 2021;592:616–622. DOI:https://doi.org/10.1038/s41586-021-03324-6.
   PubMed Web of Science ®Google Scholar